Raymond James Financial
UBX

Raymond James Financial’s Unity Biotechnology UBX Stock Holding History

Raymond James Financial’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-271
Closed -$105 – 6667
2025
Q2 		$105 Buy
+271
New +$232 ﹤0.01% 6842

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Raymond James Financial's UBX Position: Q3 2025 in Review

Raymond James Financial sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 271 shares — an estimated $105 sold.

Raymond James Financial first reported a position in UBX in Q2 2025 and held it in 1 quarter. The position peaked at $105 in Q2 2025. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Raymond James Financial reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 271 Unity Biotechnology shares in Q3 2025, an estimated $105.
  • Raymond James Financial first reported a position in Unity Biotechnology in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Unity Biotechnology position peaked at $105 in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.